Prolensa Patent Expiration

Prolensa is a drug owned by Bausch And Lomb Inc. It is protected by 9 US drug patents filed from 2013 to 2018. Out of these, 3 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 11, 2033. Details of Prolensa's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8129431 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Sep, 2025

(10 months from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517220 Bromfenac bioavailability
Nov, 2033

(9 years from now)

Active
US10085958 Bromfenac bioavailability
Nov, 2032

(8 years from now)

Active
US8871813 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(8 months ago)

Expired
US9144609 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(8 months ago)

Expired
US9561277 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(8 months ago)

Expired
US8669290 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(8 months ago)

Expired
US8927606 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(8 months ago)

Expired
US8754131 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(8 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prolensa's patents.

Given below is the list of recent legal activities going on the following patents of Prolensa.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9517220
Payment of Maintenance Fee, 8th Year, Large Entity 22 Mar, 2023 US9144609 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jun, 2022 US8927606
Payment of Maintenance Fee, 4th Year, Large Entity 30 Mar, 2022 US10085958
Payment of Maintenance Fee, 8th Year, Large Entity 14 Mar, 2022 US8871813
Payment of Maintenance Fee, 8th Year, Large Entity 01 Dec, 2021 US8754131 (Litigated)
Correspondence Address Change 30 Aug, 2021 US10085958
Correspondence Address Change 30 Aug, 2021 US9517220
Payment of Maintenance Fee, 8th Year, Large Entity 06 Aug, 2021 US8669290
Payment of Maintenance Fee, 4th Year, Large Entity 04 Jun, 2020 US9517220


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Prolensa and ongoing litigations to help you estimate the early arrival of Prolensa generic.

Prolensa's Litigations

Prolensa been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 26, 2014, against patent number US8669290. The petitioner Metrics, Inc., challenged the validity of this patent, with SENJU PHARMACEUTICAL CO., LTD. as the respondent. Click below to track the latest information on how companies are challenging Prolensa's patents.

Last updated on October 8, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8669290 April, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8754131 April, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8754131 November, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8871813 April, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8871813 November, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8927606 April, 2015 FWD Entered
(12 Sep, 2016)
Senju Pharmaceutical Co., Ltd. Lupin Ltd.
US8927606 November, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8129431 September, 2015 FWD Entered
(05 Aug, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8129431 March, 2015 FWD Entered
(28 Jul, 2016)
Senju Pharmaceutical Co., Ltd. InnoPharma, Licensing, Inc.
US8669290 March, 2015 FWD Entered
(28 Jul, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8129431 June, 2014 Terminated-Settled
(08 Jul, 2015)
Senju Pharmaceutical Co., Ltd. Metrics, Inc. c/o Duane Morris LLP
US8669290 June, 2014 Terminated-Settled
(08 Jul, 2015)
SENJU PHARMACEUTICAL CO., LTD. Metrics, Inc.


FDA has granted some exclusivities to Prolensa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Prolensa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Prolensa.

Exclusivity Information

Prolensa holds 1 exclusivities. All of its exclusivities have expired in 2016. Details of Prolensa's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Prolensa's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Prolensa's generic, the next section provides detailed information on ongoing and past EP oppositions related to Prolensa patents.

Prolensa's Oppositions Filed in EPO

Prolensa has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 30, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04702854A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP04702854A Jan, 2009 Teva Pharmaceutical Industries Ltd. Opposition procedure closed


US patents provide insights into the exclusivity only within the United States, but Prolensa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prolensa's family patents as well as insights into ongoing legal events on those patents.

Prolensa's Family Patents

Prolensa has patent protection in a total of 15 countries. It's US patent count contributes only to 40.0% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Prolensa.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Prolensa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 11, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Prolensa Generics:

Bromfenac Sodium is the generic name for the brand Prolensa. 11 different companies have already filed for the generic of Prolensa, with Lupin Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Prolensa's generic

How can I launch a generic of Prolensa before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Prolensa's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Prolensa's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Prolensa -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.0007 26 Jul, 2013 1 11 Sep, 2025 Non-Forfeiture

Alternative Brands for Prolensa

Prolensa which is used for managing ocular inflammation, postoperative inflammation, and reducing ocular pain in patients after cataract surgery., has several other brand drugs in the same treatment category and using the same active ingredient (Bromfenac Sodium). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Harrow Eye
Nevanac Used for treating ocular inflammation.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Bromfenac Sodium. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Sun Pharm
Bromsite


Apart from brand drugs containing the same ingredient, some generics have also been filed for Bromfenac Sodium, Prolensa's active ingredient. Check the complete list of approved generic manufacturers for Prolensa





About Prolensa

Prolensa is a drug owned by Bausch And Lomb Inc. It is used for managing ocular inflammation, postoperative inflammation, and reducing ocular pain in patients after cataract surgery. Prolensa uses Bromfenac Sodium as an active ingredient. Prolensa was launched by Bausch And Lomb in 2013.

Approval Date:

Prolensa was approved by FDA for market use on 05 April, 2013.

Active Ingredient:

Prolensa uses Bromfenac Sodium as the active ingredient. Check out other Drugs and Companies using Bromfenac Sodium ingredient

Treatment:

Prolensa is used for managing ocular inflammation, postoperative inflammation, and reducing ocular pain in patients after cataract surgery.

Dosage:

Prolensa is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.07% ACID SOLUTION/DROPS Prescription OPHTHALMIC